Research conducted by the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences provides evidence to support expansion of insurance plan coverage of noninvasive prenatal testing (NIPT), to women under the age of 35. It represents a first-of-its-kind published analysis of results from a risk-sharing agreement between biotechnology company Illumina, Inc. and insurer Harvard Pilgrim Health Care, conducting the research in partnership with advisory firm Real Endpoints to evaluate the impacts of the agreement.
read full article ›